Statins Block Cancer’s Immunosuppressive PD-L1 Pathway
Cancer cells package immunosuppressive PD-L1 into sEVs via UBL3, hindering immunotherapy. Researchers found widely used statins can block this process, offering a new strategy to enhance immune checkpoint therapies by reducing circulating immunosuppressive PD-L1.